Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the EUFocus on Precision ...

Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

A new machine learning model predicts the need for temporary stoma formation after intestinal resection in Crohn’s disease, ...

A new study links mitochondrial dysfunction to Crohn’s disease, shifting how scientists approach treatment and opening doors ...

Steven Frayne, aka Dynamo, has revealed he "couldn't even shuffle cards" as he opened up on a debilitating health condition.

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...